Sign in →

Test ID FMYPP Myocarditis/Pericarditis Panel


Specimen Required


Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Specimen Volume: 3 mL

Collection instructions:

Draw blood in a plain red top tube(s), serum gel tube is acceptable. Spin down and send 3 mL of serum refrigerated in a plastic vial.


Profile Information

Test ID Reporting Name Available Separately Always Performed
CXB_1 Coxsackie B(1-6) Antibodies, S No Yes
ECH_1 Echovirus Antibody Panel, Serum No Yes
FINFL Influenza Types A and B Ab, Serum No Yes
FFCPA Chlamydophila pneumoniae Ab IgG/A/M No Yes

Method Name

Complement Fixation (CF)/Immunoflourescence Assay (IFA)

Reporting Name

Myocarditis/Pericarditis Panel

Specimen Type

Serum

Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  30 days
  Ambient  7 days

Reference Values

MYOCARDITIS-PERICARDITIS PANEL

 

COXSACKIE B(1-6) ANTIBODIES, SERUM

 

    REFERENCE RANGE: <1:8

 

    INTERPRETIVE CRITERIA:

            <1:8 Antibody Not Detected

            ≥ 1:8 Antibody Detected

 

Single titers of ≥ 1:32 are indicative of recent infection. Titers of 1:8 or 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype.

 

This test was developed and its performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

 

ECHOVIRUS ANTIBODIES, SERUM

 

    REFERENCE RANGE: <1:8

 

    INTERPRETIVE CRITERIA:

            <1:8 Antibody Not Detected

            ≥ 1:8 Antibody Detected

 

Single titers ≥ 1:32 are indicative of recent infection. Titers of 1:8 and 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype.

 

This test was developed and its performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

 

INFLUENZA TYPES A AND B ANTIBODIES, SERUM

 

    REFERENCE RANGE: <1:8

 

    INTERPRETIVE CRITERIA:

            <1:8 Antibody Not Detected

            ≥ 1:8 Antibody Detected

 

Single titers of ≥ 1:64 are indicative of recent infection. Titers of 1:8 to 1:32 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis.

 

This test was developed and its performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

 

CHLAMYDOPHILA PNEUMONIAE ANTIBODIES (IgG, IgA, IgM)

 

    REFERENCE RANGE:    IgG <1:64

                                          IgA <1:16

                                          IgM <1:10

 

The immunofluorescent detection of specific antibodies to Chlamydophila pneumoniae may be complicated by cross-reactive antibodies, non-specific antibody stimulation, or past exposure to similar organisms such as C. psittaci and Chlamydia trachomatis. IgM titers of 1:10 or greater usually indicate recent infection, and any IgG titer may indicate past exposure. IgA is typically present at low titers during primary infection, but may be elevated in recurrent exposures or in chronic infection.

Day(s) Performed

Monday through Saturday

Report Available

2 to 9 days

Performing Laboratory

Quest Diagnostics

Test Classification

These assays were developed and their performance characteristics have been determined by Quest Diagnostics. They have not been cleared or approved by FDA. These assays have been validated pursuant to the CLIA regulations and are used for clinical purposes.

CPT Code Information

86658 x 11

86710 x 2

86331 x 2

86632

LOINC Code Information

Test ID Test Order Name Order LOINC Value
FMYPP Myocarditis/Pericarditis Panel Not Provided

 

Result ID Test Result Name Result LOINC Value
Z2303 Coxsackie B1 Ab 5104-5
Z2309 Echovirus 4 Ab 5143-3
Z5241 C. pneumoniae IgG 6913-8
Z0364 Influenza A Ab 5229-0
Z0365 Influenza B Ab 5230-8
Z5242 C. pneumoniae IgA 6912-0
Z2310 Echovirus 7 Ab 6922-9
Z2304 Coxsackie B2 Ab 5106-0
Z2305 Coxsackie B3 Ab 5108-6
Z2311 Echovirus 9 Ab 5147-4
Z5243 C. pneumoniae IgM 6914-6
Z5244 Interpretation 50612-1
Z2313 Echovirus 11 Ab 6708-2
Z2306 Coxsackie B4 Ab 5110-2
Z2307 Coxsackie B5 Ab 5112-8
Z2314 Echovirus 30 Ab 6392-5
Z2308 Coxsackie B6 Ab 5114-4

NY State Approved

Yes